The eagerly anticipated peptide-based FAP-targeted therapeutic drug, FAP-2286, and the highly selective peptide, PNT6555 is currently undergoing further clinical evaluation [NCT04939610 (LuMIERE) and NCT05432193 (FRONTIER)] owing to their outstanding preclinical dose-dependent anti-tumor effects and initial clinical feasibility (Figure 3B) 50-52. Here, FAP is linked to neoplasm.